Kiromic Biopharma, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
Kiromic BioPharma's 2024 10-K filing highlights ongoing losses, a need for additional funding, and substantial doubt about the company's ability to continue as a going concern.
Kiromic BioPharma has filed an amendment to its annual report to include previously omitted information and director signatures.
Kiromic BioPharma's 2023 annual report highlights progress in its Deltacel clinical trial and ongoing financial challenges.